tiprankstipranks
Trending News
More News >

Jiangsu Hengrui Pharma Gains Approval for New Drug Indication

Story Highlights
  • Jiangsu Hengrui Pharmaceuticals received approval for Ivarmacitinib Sulfate Tablets.
  • The approval enhances the company’s market position and treatment options for alopecia areata.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Jiangsu Hengrui Pharma Gains Approval for New Drug Indication

Don’t Miss TipRanks’ Half-Year Sale

Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H ( (HK:1276) ) has provided an announcement.

Jiangsu Hengrui Pharmaceuticals Co., Ltd. has received approval from the National Medical Products Administration for a new indication of its Class 1 innovative drug, Ivarmacitinib Sulfate Tablets, for the treatment of severe alopecia areata in adults. This approval marks a significant advancement for the company, potentially enhancing its market position and offering new treatment options for patients suffering from this chronic condition.

More about Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H

Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a pharmaceutical company based in China, focusing on the development and production of innovative drugs. The company operates in the pharmaceutical industry and is known for its research and development of new medications, particularly in the field of oncology and other therapeutic areas.

Average Trading Volume: 6,461,033

Current Market Cap: HK$374.9B

For detailed information about 1276 stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1